Health Care Equipment

ChronoScale

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

APLD

CLOU

IDGT

DTCR

APLX

Applied Digital Corp (APLD) stock surged 12.07% to $46.22 following the spin-off of its cloud business into ChronoScale Corporation, which will focus on AI workloads. APLD retains a 97% stake in ChronoScale. CEO Wes Cummins emphasized the split aims to enhance efficiency between predictable data center hosting and higher-growth cloud computing. The restructuring is supported by a $300 million loan from Goldman Sachs for a new AI data center in North Dakota. APLD is currently in a strong uptrend, trading significantly above its key moving averages.

Fidelity

Applied Digital

Global X Cloud Computing ETF

iShares US Digital Infrastructure and Real Estate ETF

Global X Data Center & Dgtl Infrs ETF

Tradr 2X Long APLD Daily ETF

EKSO Bionics

Goldman Sachs

S&P 500

GS Hldg R

Why Applied Digital Stock Is Up Following Cloud Spin-Off

CHRN

SRVR

XDAT

CHRN Stock Just Started Trading as Applied Digital Spins Off ChronoScale. How to Play Shares Here.

Barchart Option

Pacer Data & Infrastructure Real Estate ETF

Franklin Exponential Data ETF

CHRN Stock Just Started Trading as Applied Digital Spins Off ChronoScale. How to Play Shares Here.

EKSO

HUMN

Hypershell, a Chinese startup, is developing lightweight exoskeletons aimed at enhancing human capability for outdoor and everyday use. By combining motors and sensors, their products assist with walking and climbing, focusing on aesthetics and ease of use to encourage consumer adoption. Targeting outdoor enthusiasts initially, Hypershell plans to expand into North America and Europe. The company faces challenges in reducing costs and validating scalable applications, with current prices ranging from $899 to $1,999. As technology advances, the transition to mainstream consumer use is expected to be gradual, emphasizing iterative development and user feedback.

TechNode

Roundhill Humanoid Robotics ETF

Betting on human augmentation, will lightweight exoskeletons go mainstream?

Earnings Watch

EKSO Bionics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 2.141 M

SBIO

Insider activity at EKSO BIONICS on March 20, 2026, saw COO Jason C Jones and CFO Jerome Wong each purchase 1,308 shares, indicating strong executive confidence. However, the company faces significant IP risks, including trade-secret infringement and dependence on co-owned patents, which could impact future innovations. Analysts view EKSO stock as Neutral due to ongoing losses and cash burn, despite some positive technical indicators. The current market cap is $37.06M, with a year-to-date price performance of 20.37%.

Tip Ranks

Invesco Biotechnology & Genome ETF

SPDR S&P Health Equip

iShares US Medical Devices

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Top EKSO BIONICS Insiders Make Bold Moves With Fresh Share Purchases

EKSO Bionics | 10-K: FY2025 Revenue Misses Estimate at USD 12.8 M

ANIK

NBSE.ESC

Eikon Therapeutics, Inc is set to IPO on February 5, 2026, on NASDAQ under the ticker EIKN. The shares are expected to be priced between $16.00 and $18.00 each, with a 180-day insider lock-up period ending on August 4, 2026. The company focuses on developing innovative medicines for serious unmet medical needs.

fidelity

Anika Therap

ESC NEUBASE THERAPEUTI

Preview: Eikon Therapeutics, Inc Set To IPO Tomorrow

Ekso Bionics (EKSO) announced a private placement of $5.8 million on January 20, 2026, involving 5,852 shares of Series B preferred stock and warrants for up to 360,000 common shares. Each preferred share is valued at $1,000 and can be converted into common shares at any time.

Direxion S&P Biotech Bear 3X

Ekso Bionics prices $5.8M private placement

Ownership	%Owned	Share Chg	Report Date
Applied Digital Corporation	97.01%	No Change	05/05/2026
Armistice Capital LLC	0.13%	No Change	31/03/2026
Resources Management Corp	0%	No Change	31/03/2026

ChronoScale(CHRN.US)

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

Why Applied Digital Stock Is Up Following Cloud Spin-Off

CHRN Stock Just Started Trading as Applied Digital Spins Off ChronoScale. How to Play Shares Here.

Betting on human augmentation, will lightweight exoskeletons go mainstream?

EKSO Bionics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 2.141 M

Top EKSO BIONICS Insiders Make Bold Moves With Fresh Share Purchases